Literature DB >> 26239384

The complex liaison between cachexia and tumor burden (Review).

Andrea De Lerma Barbaro1.   

Abstract

Cachexia is a wasting syndrome that afflicts end-stage cancer patients. Whereas a consensus statement for a definition of cachexia recently has been accomplished, a useful measurement for this condition at present is lacking. The aim of the present review is to discuss the advantage of introducing the measurement of tumor burden for a better overall evaluation of cachexia. Our suggestion ensues from a somewhat novel perspective in the field of infectious disease research where a careful measurement of the pathogen load, between i.e. different host genotypes, leads to the definition of the concept of tolerance to the infectious insult. Indeed tolerance concurs, together the more classical resistance, in maintaining the host reproductive fitness or health state. Noticeably a similar reasoning may apply to tumor biology as well. Whereas the extent of cachexia increases with tumor burden, the relationship between these two correlates of tumor progression fluctuates in a broad range. We have selected from the literature studies in the rodent model where significant variation in the course of the wasting illness during cancer was observed and quantitatively assessed comparing experimental groups marked by different genotype, drug treatment, diet or gender. These studies may be further classified in two categories: the former where the experimental condition associated to milder cachexia is accompanied to a lesser tumor burden, the latter where the inhibition of cachexia results disentangled from the tumor burden, that is the whole number of cancer cells results unchanged or even, paradoxically, is increased. In addition we survey, even in the context of human malignancy, the significance and feasibility of plotting quantitative estimates of cachexia against the whole tumor burden. Ultimately, the principal endeavor of introducing the measurement of tumor burden, in both experimental and clinical oncology, may be to achieve a better assessment of the inter-individual variation in the host vulnerability to cancer cachexia.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26239384     DOI: 10.3892/or.2015.4164

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  The myokine Fibcd1 is an endogenous determinant of myofiber size and mitigates cancer-induced myofiber atrophy.

Authors:  Mamta Rai; Liam C Hunt; Flavia A Graca; Anna Stephan; Yong-Dong Wang; Brittney Gordon; Ruishan Wang; Giovanni Quarato; Beisi Xu; Yiping Fan; Myriam Labelle; Fabio Demontis
Journal:  Nat Commun       Date:  2022-05-02       Impact factor: 17.694

2.  Cachexia, and not obesity, prior to pancreatic cancer diagnosis worsens survival and is negated by chemotherapy.

Authors:  Andrew E Hendifar; Jonathan I Chang; Brian Z Huang; Richard Tuli; Bechien U Wu
Journal:  J Gastrointest Oncol       Date:  2018-02

3.  Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies.

Authors:  Si-Cong Ma; Xin-Ran Tang; Li-Li Long; Xue Bai; Jian-Guo Zhou; Zhi-Jiao Duan; Jian Wang; Qiang John Fu; Hong-Bo Zhu; Xue-Jun Guo; Yan-Pei Zhang; Ze-Qin Guo; De-Hua Wu; Zhong-Yi Dong
Journal:  Oncoimmunology       Date:  2021-04-26       Impact factor: 8.110

4.  Withaferin A and Ovarian Cancer Antagonistically Regulate Skeletal Muscle Mass.

Authors:  Alex R Straughn; Natia Q Kelm; Sham S Kakar
Journal:  Front Cell Dev Biol       Date:  2021-02-25

5.  Local and Systemic Cytokine Profiling for Pancreatic Ductal Adenocarcinoma to Study Cancer Cachexia in an Era of Precision Medicine.

Authors:  Michael H Gerber; Patrick W Underwood; Sarah M Judge; Daniel Delitto; Andrea E Delitto; Rachel L Nosacka; Bayli B DiVita; Ryan M Thomas; Jennifer B Permuth; Steven J Hughes; Shannon M Wallet; Andrew R Judge; Jose G Trevino
Journal:  Int J Mol Sci       Date:  2018-12-01       Impact factor: 5.923

6.  Computed tomography with segmentation and quantification of individual organs in a D. melanogaster tumor model.

Authors:  Petter Holland; Eduardo Martin Quintana; Rojyar Khezri; Todd Andrew Schoborg; Tor Erik Rusten
Journal:  Sci Rep       Date:  2022-02-08       Impact factor: 4.379

7.  Anticachectic regulator analysis reveals Perp-dependent antitumorigenic properties of 3-methyladenine in pancreatic cancer.

Authors:  Aneesha Dasgupta; Paige C Arneson-Wissink; Rebecca E Schmitt; Dong Seong Cho; Alexandra M Ducharme; Tara L Hogenson; Eugene W Krueger; William R Bamlet; Lizhi Zhang; Gina L Razidlo; Martin E Fernandez-Zapico; Jason D Doles
Journal:  JCI Insight       Date:  2022-01-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.